Mary Immaculate Hospital LLC
Mary Immaculate Hospital LLC was paid $24.51M by Medicaid between Jan 2018 and Dec 2024, across 232 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
NEWPORT NEWS, VA 23602
Next to other General Acute Care Hospital providers in Virginia
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,776 | $1.84M | |
| 2019 | 107,872 | $2.71M | |
| 2020 | 89,473 | $2.92M | |
| 2021 | 123,148 | $3.95M | |
| 2022 | 122,223 | $4.36M | |
| 2023 | 132,233 | $4.50M | |
| 2024incomplete | 93,181 | $4.23M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 32,905 | 27,692 | $4.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 24,076 | 20,217 | $4.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 14,961 | 12,518 | $2.59M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.7% | 7,732 | 6,270 | $2.14M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.4% | 10,108 | 8,436 | $1.32M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 4,505 | 3,942 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 22,187 | 5,554 | $872K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.3% | 16,873 | 4,917 | $798K |
| 59025 | Fetal non-stress test | 3.2% | 5,315 | 3,458 | $796K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 3,876 | 3,351 | $683K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 4,321 | 3,626 | $376K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 2,596 | 2,247 | $358K |
220 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 1,327 | $341K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,653 | $325K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 1,423 | $312K |
| 93975 | 1.0% | 2,444 | $247K | |
| G0378 | Hospital observation service, per hour | <1% | 2,058 | $230K |
| 74240 | <1% | 2,177 | $227K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,283 | $187K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,053 | $186K |
| 97162 | <1% | 1,669 | $182K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,335 | $178K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,022 | $175K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 14,226 | $164K |
| 97161 | <1% | 1,812 | $155K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,059 | $138K |
| 80053 | Comprehensive metabolic panel | <1% | 30,768 | $117K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,174 | $107K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 909 | $95K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 672 | $91K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,789 | $84K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,406 | $54K |
| 93971 | <1% | 636 | $52K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 155 | $49K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,885 | $46K |
| 97016 | <1% | 1,826 | $42K | |
| C1776 | Joint device (implantable) | <1% | 345 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,893 | $40K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 971 | $37K |
| 97116 | <1% | 1,670 | $36K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,220 | $36K |
| 83880 | <1% | 2,934 | $25K | |
| 97602 | <1% | 164 | $25K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,309 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,349 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,529 | $22K |
| 76830 | Ultrasound, transvaginal | <1% | 366 | $20K |
| 87040 | <1% | 2,638 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,040 | $15K |
| 82553 | <1% | 6,666 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,007 | $14K |
| 86850 | <1% | 4,693 | $14K | |
| 49083 | <1% | 27 | $14K | |
| 97165 | <1% | 253 | $13K | |
| 80076 | <1% | 2,619 | $13K | |
| 0346T | <1% | 218 | $12K | |
| 85379 | <1% | 2,678 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,906 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 282 | $10K |
| 76942 | <1% | 211 | $10K | |
| 84484 | <1% | 14,256 | $10K | |
| 93970 | <1% | 70 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,971 | $10K |
| 82107 | <1% | 432 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,138 | $8K |
| 85027 | <1% | 3,571 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 848 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,803 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,387 | $7K |
| 85610 | <1% | 4,932 | $7K | |
| 84703 | <1% | 4,921 | $5K | |
| 86900 | <1% | 5,445 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,949 | $5K |
| 85014 | <1% | 1,183 | $5K | |
| 88307 | <1% | 459 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,227 | $5K |
| 87521 | Neg quan hep c or qual rna | <1% | 276 | $5K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,305 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,618 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,796 | $4K |
| 87641 | <1% | 413 | $4K | |
| 82728 | <1% | 688 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,221 | $4K |
| J3490 | Unclassified drugs | <1% | 10,399 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,061 | $4K |
| 81025 | <1% | 13,268 | $4K | |
| 81001 | <1% | 16,736 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,135 | $3K |
| 73630 | <1% | 923 | $3K | |
| 82962 | <1% | 8,993 | $3K | |
| 93976 | <1% | 53 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,136 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,291 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,671 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,875 | $3K |
| 86901 | <1% | 5,442 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 332 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 770 | $3K |
| 83540 | <1% | 830 | $3K | |
| 83605 | <1% | 2,533 | $2K | |
| 90715 | <1% | 141 | $2K | |
| 83735 | <1% | 8,485 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,424 | $2K |
| 81003 | <1% | 11,624 | $2K | |
| 80143 | <1% | 386 | $2K | |
| 80179 | <1% | 374 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,708 | $2K |
| 74018 | <1% | 788 | $2K | |
| 72110 | <1% | 192 | $2K | |
| 83690 | <1% | 11,524 | $2K | |
| 96376 | <1% | 3,683 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 320 | $2K |
| 84702 | <1% | 2,909 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,304 | $2K |
| 99218 | <1% | 149 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,229 | $1K |
| 85018 | <1% | 1,109 | $1K | |
| 73610 | <1% | 625 | $1K | |
| 82550 | <1% | 7,281 | $1K | |
| 85730 | <1% | 2,712 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,135 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,108 | $1K |
| 73130 | <1% | 369 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,681 | $996.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 613 | $983.67 |
| 82607 | <1% | 132 | $967.20 | |
| 73030 | <1% | 408 | $922.82 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,405 | $906.84 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,491 | $879.18 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,615 | $866.77 |
| 82731 | <1% | 42 | $762.86 | |
| 73564 | <1% | 535 | $725.09 | |
| 80050 | General health panel | <1% | 142 | $704.18 |
| 82077 | <1% | 2,150 | $700.24 | |
| 87070 | <1% | 4,239 | $680.58 | |
| 87210 | <1% | 3,840 | $624.06 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 372 | $613.58 |
| 87077 | <1% | 2,126 | $584.86 | |
| 84439 | <1% | 146 | $528.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,689 | $492.20 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 16 | $441.68 |
| 87081 | <1% | 1,010 | $395.80 | |
| C9399 | Unclassified drugs or biologicals | <1% | 70 | $383.48 |
| 84112 | <1% | 77 | $380.93 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,381 | $367.95 |
| 86704 | <1% | 59 | $359.24 | |
| 82746 | <1% | 95 | $351.22 | |
| 74022 | <1% | 188 | $332.08 | |
| 87186 | <1% | 1,836 | $315.57 | |
| 84425 | <1% | 26 | $314.14 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 28 | $313.65 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 90 | $309.61 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,289 | $299.71 |
| 87807 | <1% | 587 | $288.11 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 151 | $284.82 |
| 85652 | <1% | 292 | $280.50 | |
| 86708 | <1% | 73 | $279.31 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,003 | $272.87 |
| 86706 | <1% | 74 | $260.50 | |
| 74220 | <1% | 15 | $254.12 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 767 | $230.32 |
| 80061 | Lipid panel | <1% | 63 | $230.30 |
| 83550 | <1% | 76 | $228.33 | |
| 73562 | <1% | 304 | $223.28 | |
| 87340 | <1% | 70 | $206.43 | |
| 90686 | <1% | 16 | $198.82 | |
| 97166 | <1% | 15 | $195.24 | |
| 94762 | <1% | 194 | $153.37 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $147.93 |
| 0100U | <1% | 40 | $142.42 | |
| 86677 | <1% | 18 | $133.27 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,476 | $131.64 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 611 | $120.89 |
| 76981 | <1% | 273 | $113.82 | |
| J1815 | Injection, insulin, per 5 units | <1% | 42 | $106.72 |
| 73502 | <1% | 15 | $89.30 | |
| 80047 | <1% | 12 | $85.41 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,426 | $83.87 |
| 84132 | <1% | 70 | $78.84 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 777 | $72.73 |
| 84550 | <1% | 105 | $69.25 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 839 | $67.61 |
| 88304 | <1% | 22 | $63.12 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 825 | $62.70 |
| 87147 | <1% | 806 | $47.82 | |
| 82140 | <1% | 17 | $41.29 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,733 | $36.87 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 732 | $32.21 |
| 87205 | <1% | 168 | $31.54 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 706 | $30.78 |
| 73090 | <1% | 13 | $29.63 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 504 | $26.80 |
| 87088 | <1% | 58 | $19.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 284 | $14.85 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 86 | $13.42 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 312 | $11.23 |
| 82570 | <1% | 35 | $6.01 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 126 | $5.57 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 217 | $4.87 |
| 84156 | <1% | 57 | $2.68 | |
| 83615 | <1% | 16 | $2.68 | |
| C1769 | Guide wire | <1% | 126 | $2.50 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 35 | $0.54 |
| 73110 | 0% | 95 | $0.00 | |
| 99152 | 0% | 18 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 288 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 428 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 173 | $0.00 |
| C1729 | Catheter, drainage | 0% | 24 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 82 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 123 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 55 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 114 | $0.00 |
| 96367 | 0% | 15 | $0.00 | |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | 0% | 13 | $0.00 |
| 89051 | 0% | 62 | $0.00 | |
| 88313 | 0% | 13 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 356 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,039 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 16 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 222 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 540 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 127 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 291 | $0.00 |
| 82803 | 0% | 92 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 25 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 74 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 86 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 40 | $0.00 |
| 94760 | 0% | 67 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 13 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 189 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.